Status:
ACTIVE_NOT_RECRUITING
LTFU Study of Subjects With Cervical SCI Who Received AST-OPC1
Lead Sponsor:
Lineage Cell Therapeutics, Inc.
Conditions:
Spinal Cord Injuries
Eligibility:
All Genders
18-69 years
Brief Summary
This is a LTFU study for cervical SCI subjects that were administered AST-OPC1 cells in the main study AST-OPC1-01.
Detailed Description
Study AST-OPC1-02 is a Phase 1/2a open-label, multi-center long term follow-up (LTFU) study for twenty-five (25) subjects with cervical SCI that were administered AST-OPC1 cells in the main dose-escal...
Eligibility Criteria
Inclusion
- Subjects who received AST-OPC1 under Study AST-OPC1-01
- Reconfirmation of consent for long-term follow-up
Exclusion
- •Subjects who, for geographic or compliance reasons, are inappropriate candidates for participation in a long-term follow-up study in the opinion of the Investigator
Key Trial Info
Start Date :
June 13 2018
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
January 14 2033
Estimated Enrollment :
25 Patients enrolled
Trial Details
Trial ID
NCT05975424
Start Date
June 13 2018
End Date
January 14 2033
Last Update
August 21 2024
Active Locations (6)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Southern California
Los Angeles, California, United States, 90033
2
Stanford University
Palo Alto, California, United States, 94304
3
Shepherd Center
Atlanta, Georgia, United States, 30309
4
RUSH University Medical Center
Chicago, Illinois, United States, 60612